Vincerx Pharma, Inc. Common Stock
VINC
VINC was delisted on the 22nd of April, 2025.
22 hedge funds and large institutions have $1.26M invested in Vincerx Pharma, Inc. Common Stock in 2024 Q4 according to their latest regulatory filings, with 2 funds opening new positions, 4 increasing their positions, 8 reducing their positions, and 8 closing their positions.
21% less funds holding
Funds holding: 28 → 22 (-6)
50% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 8
75% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 8
84% less capital invested
Capital invested by funds: $7.9M → $1.26M (-$6.64M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
+$30.4K |
| 2 |
HF
HRT Financial
New York
|
+$14.8K |
| 3 |
Focus Partners Wealth
Boston,
Massachusetts
|
+$3.58K |
| 4 |
Morgan Stanley
New York
|
+$112 |
| 5 |
Bank of America
Charlotte,
North Carolina
|
+$7 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PM
Prosight Management
Dallas,
Texas
|
-$1.58M |
| 2 |
AC
Armistice Capital
New York
|
-$702K |
| 3 |
Point72 Asset Management
Stamford,
Connecticut
|
-$483K |
| 4 |
ECM
ExodusPoint Capital Management
New York
|
-$388K |
| 5 |
Marshall Wace
London,
United Kingdom
|
-$255K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
26
Marshall Wace
London,
United Kingdom
| – | -$255K | -17,678 | Closed |
|
|
XT
27
XTX Topco
George Town,
Cayman Islands
| – | -$13.1K | -916 | Closed |
|
28
Two Sigma Investments
New York
| – | -$10.2K | -711 | Closed |
|
|
HCM
29
Hollencrest Capital Management
Newport Beach,
California
| – | -$7.16K | -500 | Closed |
|
|
TRCT
30
Tower Research Capital (TRC)
New York
| – | -$5K | -349 | Closed |
|
VINC Hedge Fund Activity: Q4 2024 in Review
22 of the 7,593 institutional investors tracked by Wall St. Rank reported a position in Vincerx Pharma, Inc. Common Stock (VINC) for Q4 2024, worth a combined $1.26M — down 84% from $7.9M a quarter earlier.
Sellers outnumbered buyers: 8 funds closed out of VINC and 2 opened new positions — a net loss of 6 holders — while 8 trimmed existing stakes and 4 added.
The largest buyer was UBS Group, adding an estimated $30.4K. The largest seller was Prosight Management, exiting entirely with an estimated $1.58M sold.
- 22 institutional investors held Vincerx Pharma, Inc. Common Stock (VINC) as of Q4 2024, down from 28 in Q3 2024.
- Funds reported $1.26M of Vincerx Pharma, Inc. Common Stock stock for Q4 2024, down 84% quarter-over-quarter.
- 2 funds opened new Vincerx Pharma, Inc. Common Stock positions in Q4 2024 and 8 closed out, a net change of -6 holders.
- The largest Vincerx Pharma, Inc. Common Stock buyer in Q4 2024 was UBS Group, an estimated $30.4K added.
- The largest Vincerx Pharma, Inc. Common Stock seller in Q4 2024 was Prosight Management, an estimated $1.58M sold.
Based on aggregated 13F filings for Q4 2024.